Bupropion HCL ER
SOL #: SPE2D2-21-R-0105Solicitation
Overview
Buyer
DEPT OF DEFENSE
Defense Logistics Agency
DLA TROOP SUPPORT
PHILADELPHIA, PA, 19111, United States
Place of Performance
Place of performance not available
NAICS
Pharmaceutical Preparation Manufacturing (325412)
PSC
Drugs And Biologicals (6505)
Set Aside
No set aside specified
Original Source
Timeline
1
Posted
Mar 11, 2021
2
Last Updated
Sep 15, 2025
3
Submission Deadline
Feb 15, 2022, 8:00 PM
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Modification P00008 SPE2D223D0002 is issued to invoke option year 3 for Bupropion HCL ER National Contract.
Modification P00007 SPE2D223D0002 is issued in accordance with DoD Class Deviation 2025-O0003 and Class Deviation 2025-O0004 into subject solicitation.
Modification P00006 SPE2D223D0002 is issued to invoke option year 2 for Bupropion HCL ER National Contract.
Modification P00005 SPE2D223D0002 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation.
BUPROPION HCL ER NATIONAL CONTRACTS SOLICITATION
People
Points of Contact
Kyle LewickiPRIMARY
Jason C. WraySECONDARY